Genelux (GNLX) Revenue & Revenue Breakdown
Genelux Revenue Highlights
Latest Revenue (Y)
$8.00K
Genelux Revenue by Period
Genelux Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $8.00K | -95.29% |
| 2023-12-31 | $170.00K | -98.46% |
| 2022-12-31 | $11.07M | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | - |
Genelux generated $8.00K in revenue during NA 2024, up -95.29% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Genelux Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | - | -100.00% |
| 2024-12-31 | $452.00K | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | -100.00% |
| 2024-03-31 | $8.00K | -99.45% |
| 2023-12-31 | $1.46M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | -100.00% |
| 2023-03-31 | $170.00K | 150.00% |
| 2022-12-31 | $68.00K | -99.38% |
| 2022-09-30 | $11.00M | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | - |
Genelux generated - in revenue during Q1 2025, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Genelux Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CDXS | Codexis | $59.34M | $7.54M |
| CGEN | Compugen | $33.46M | $2.56M |
| GNFT | Genfit | $28.57M | $17.08M |
| OABI | OmniAb | $26.39M | $4.15M |
| IVVD | Invivyd | $25.38M | $11.30M |
| MDWD | MediWound | $18.69M | $4.96M |
| PYXS | Pyxis Oncology | $16.15M | - |
| GNLX | Genelux | $8.00K | - |
| CRBP | Corbus Pharmaceuticals | - | - |
| SLS | SELLAS Life Sciences Group | - | - |
| EPRX | Eupraxia Pharmaceuticals | - | - |